Sahajanand Medical Technologies Limited
Against an issue price of ₹344. Split- and bonus-adjusted official closes — a past move, never a forecast.
Sahajanand Medical Technologies Limited was a mainboard initial public offer.
The book was open from 15 October 2026 to 19 October 2026.
The issue was priced at ₹344 a share, from a band of ₹327 to ₹344.
As of the exchange's 19-Oct-2026 19:00:00 update the book was subscribed 14.2 times the shares on offer, counting bids on NSE and BSE together.
Against their reserved portions: qualified institutional buyers 34.70 times, non-institutional investors 14.64 times, retail investors 3.03 times and employees 0.37 times. Those portions add up to the whole offer; the sub-categories below each one are already counted inside it.
1.25 crore shares were bid at cut-off — applications that accept whatever price the issue is finally set at rather than naming one.
10 anchor investors were allotted shares before the book opened, worth ₹140 crore.
The shares listed on 23 October 2026.
The last official close on file is ₹488 (5 November 2026), which is 41.8% above the issue price.
It now trades as SMT, and its filed financials are on its company page.
Shares sold in the issue at ₹344 last closed at ₹487.75.
See SMT’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- Registrar
- MUFG Intime India Private Limited
- Lead managers
- Motilal Oswal Investment Advisors Limited
- Avendus Capital Private Limited
- HSBC Securities and Capital Markets (India) Private Limited
- Nuvama Wealth Management Limited
- Bidding opens15 Oct 2026
- Bidding closes19 Oct 2026
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing23 Oct 2026
Investors have bid for 14.20 times the shares on offer. Each category below has its own reserved portion, and those portions add up to the whole offer.
Bids placed on NSE alone, excluding BSE. It is smaller than the 14.20x headline above and the two must never be compared or added together.
Every bid names a price, or accepts whatever the final price turns out to be. This shows how many shares have been bid for at each price or above it — so the bar at the top of the band counts only the bids willing to pay it.
The columns are near-identical because they are: demand falls only 0.04% between ₹327 and ₹344, so almost every bid was willing to pay the top of the band. The axis starts at zero — the flatness is the finding, not a missing scale.
These accept whatever price the issue is finally set at, so they have no place on the price axis and are not in the chart.
How much of the demand falls away between the bottom and the top of the band.
Cumulative shares bid at or above each price in the band, from the exchange's own demand schedule. Bids placed at cut-off carry no price and are counted separately.
Anchor investors are institutions allotted shares one working day before public bidding opens, at a price fixed then. Their shares are locked in for a set period. At least 1 of them are domestic mutual funds; we could not classify 9 of the names either way.
| NIPPON LIFE INDIA TRUSTEE LTD - A/C NIPPON INDIA SMALL CAP FUNDmutual fund | ₹39.4 cr |
| DSP HEALTHCARE FUND | ₹20.3 cr |
| ALLIANZ GLOBAL INVESTORS FUND - ALLIANZ INDIA EQUITY | ₹15 cr |
| INVESCO INDIA PHARMA & HEALTHCARE FUND | ₹15 cr |
| UTI - HEALTHCARE FUND | ₹15 cr |
| NATIXIS INTERNATIONAL FUNDS (LUX) I - LOOMIS SAYLES GLOBAL | ₹11 cr |
| TATA AIA LIFE INSURANCE COMPANY LIMITED A/C WHOLE LIFE AGGRESSIVE GROWTH FUND ULIF 010 04/01/07 WLA 110 | ₹10 cr |
| WHITEOAK CAPITAL FLEXI CAP FUND | ₹6.3 cr |
| WHITEOAK CAPITAL PHARMA AND HEALTHCARE FUND | ₹5 cr |
| WHITEOAK CAPITAL MULTI ASSET ALLOCATION FUND | ₹3 cr |
From the issuer’s anchor allotment filing. A record of who was allotted what — not a recommendation.
- Anchor investors — first trancheSEBI ICDR 2018 Reg. 32(5)(b) — 50% of the anchor allocation, 30 days from allotment22 Nov 202650% of this tranche
- Anchor investors — second trancheSEBI ICDR 2018 Reg. 32(5)(a) — the remaining 50% of the anchor allocation, 90 days from allotment21 Jan 202750% of this tranche
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment23 Apr 2027whole tranche releases on this date
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment23 Apr 2028whole tranche releases on this date
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The peer table is printed in the offer document's "Basis for Offer Price" chapter; we have not extracted it for this issue yet.
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Avendus Capital Private Limited 2024 – 2026 | 9 4 measurable | +0.7% | 1 of 2 | — | 0 of 2 |
HSBC Securities and Capital Markets Private Limited 2023 – 2026 | 14 4 measurable | +8.0% | 1 of 2 | 1 of 3 | 0 of 1 |
Motilal Oswal Investment Advisors Limited 2022 – 2026 | 43 11 measurable | +16.4% | 4 of 9 | 2 of 5 | 0 of 1 |
Nuvama Wealth Management Limited 2023 – 2026 | 22 7 measurable | +6.1% | 1 of 2 | 0 of 1 | 0 of 1 |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Mufg Intime India Private Limited 2025 – 2026 | 90 29 measurable | +13.2% | 7 of 24 | 1 of 4 | 2 of 6 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive21 Oct 2026NO_TABLE
- Red herring prospectus (RHP)· ZIP · exchange archiveNO_TABLE
- Draft red herring prospectus (DRHP)· PDF · exchange archive6 Aug 2025
- Draft red herring prospectus (DRHP)· ZIP · exchange archive27 Sept 2021
- Anchor investor allotment· ZIP · exchange archive
- Financial ratios advertisement· ZIP · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.